ArticleBMC cancer2025
Comprehensive cancer analysis reveals CFH as an immune-related and prognostic marker.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Validation of a Crotonylation-Related Prognostic Risk Model for Cholangiocarcinoma Based on Integrative Transcriptome Analysis.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundComplement Factor H (CFH) has been reported as an indispensable role in innate and adaptive immunity. Despite increasing interest in CFH, its clinicopathological implications and immunological mechanisms across different cancers remain unclear and are currently under debate.
methodsInvestigating the function of CFH in 23 tumor types using The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), The Tumor Immune Estimation Resource 2.0 (TIMER2.0) database, cBioportal, Human Protein Atlas (HPA). Then using Cell Counting Kit-8 (CCK8) assay, plate colony formation assay, and wound healing assay to detect the biological function of CFH in vitro.
resultsCFH exhibited dysregulated expression across multiple cancers, with associations observed between its expression levels, immune cell infiltration, clinical stage, and immune subtype. Additionally, CFH was critically involved in shaping the tumor microenvironment and regulating immune responses. The upregulated expression level of CFH was significantly related to tumor-infiltrating immune cells (TICs), tumor mutational burden (TMB), and microsatellite instability (MSI). Functionally, we found that knockdown of CFH could inhibit the tumor cell proliferation and invasion.
conclusionsThis study implies the potential prognostic and immunological role of CFH in various cancers, and CFH could act as a biomarker for tumor immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.